65 results about "Chelating ligands" patented technology

A nano composite, a nanoparticle ink composition including a solvent and the nanocomposite, and a light-emitting device including a first electrode, a second electrode facing the first electrode, and an interlayer between the first electrode and the second electrode, wherein the interlayer includes an emission layer, and at least one layer included in the interlayer is made from the nanoparticle ink composition. The nano composite includes: a metal oxide nanoparticle; and a chelating ligand bonded to a surface of the nanoparticle and including a cyclic moiety.

Provided is a compound for double targeting of a fibroblast activation protein and an integrin subtype, comprising: (i) a chelating ligand moiety (CL); (ii) a first targeting moiety (BT); and (iii) a second targeting moiety (CY), wherein (i), (ii), and (iii) are fixed, combined, or connected by means of any L; BT is a fibroblast activation protein (FAP)-specific binding ligand structure; CY is an integrin subunit αvβ3 or αvβ6-specific binding ligand structure; L is selected from one or a combination of L1, L2, L3, L4, L5, L6, and L7; L1, L2, L3, L4, L5, L6, and L7 are each independently a key, a monovalent joint, a divalent joint, or a trivalent joint. Also provided are a preparation method for the compound and use thereof.

The invention discloses a Nectin-4 targeted nucleic acid aptamer nuclide diagnosis and treatment integrated probe, and relates to the field of biotechnology and diagnosis and treatment integration and treatment, and the diagnosis and treatment integrated probe comprises a Nectin-4 targeted nucleic acid aptamer, a nuclide chelating ligand and a nuclide for marking; wherein the Nectin-4 targeting nucleic acid aptamer has a base sequence as shown in any one of SEQ ID NO.1-3, or has a base sequence of which the homology with the base sequence as shown in any one of SEQ ID NO.1-3 is more than 80%. The diagnosis and treatment integrated probe prepared by the invention can be applied to PET / CT diagnosis and internal irradiation radioactive therapy, on one hand, non-invasive visual molecular imaging of Nectin-4 receptor protein overexpression tumors is realized, and on the other hand, radioactive therapy of malignant bladder cancer is further realized; the probe is good in specific targeting effect and high in tumor uptake and has a diagnosis and treatment integrated function.

This invention discloses a catalytic cracking co-catalyst with high resistance to thermal abrasion, comprising a molecular sieve, a matrix, a binder, and a binder modifier. The molecular sieve has an MFI structure, and the molecular sieve with a pore diameter less than 0.7 nm accounts for 50 wt% to 100 wt% of the total molecular sieve. The matrix is ​​composed of a γ-alumina precursor with a colloidal index ≤ 50% and clay. The binder is prepared from phosphorus-containing and aluminum-containing compounds. The raw materials for the binder modifier include multi-chelate ligands, precursors of at least two coordination metals, alcohols, and organic acids. The binder, binder modifier, and matrix are all mixed in a high-shear emulsifier. Compared with existing catalytic cracking co-catalysts for propylene and octane number, the catalytic cracking co-catalyst provided by this invention has higher resistance to thermal abrasion, larger pore volume, and higher molecular sieve content.

This invention belongs to the field of food processing technology, specifically providing a method for preparing antioxidant zinc chelate peptides, comprising the following steps: inoculating a protein solution with a compound microbial agent for fermentation; the compound microbial agent includes *Lactobacillus plantarum* and *Saccharomyces cerevisiae*; after enzymatic hydrolysis and debittering of the fermentation broth, the antioxidant peptides are separated and dried to obtain the antioxidant peptides; the antioxidant peptides are dissolved in water to prepare a peptide solution, and a zinc source is added to the peptide solution to carry out a chelation reaction; the supernatant is collected, and the precipitate is collected by alcohol precipitation to obtain the antioxidant zinc chelate peptides. This method uses low molecular weight peptides prepared by dual-microbial synergistic multi-enzyme hydrolysis as chelating ligands, which chelate with zinc ions under mild conditions to maximize the preservation of biological activity, achieving a dual enhancement of chelation capacity and antioxidant activity, and achieving a unity of high chelation rate, high antioxidant activity, high stability and good flavor. The process is green, safe, and leaves no organic solvent residue, making it suitable for large-scale industrial production.

The present application relates to a cage-like chelate, a targeted cage-like chelating ligand, and a complex and the use thereof. Provided in the present application is a cage-like chelate, which has a skeleton structure with more diverse modifiable sites and a higher flexibility, and has broad-spectrum adaptability. The cage-like chelate and the targeted cage-like ligand formed thereby can form a compound with a higher targeting ability and stability after complexation with a nuclide, thereby mitigating the daughter nuclide recoil effect of alpha nuclide-labeled drugs in organisms, and reducing toxic and side effects of alpha decay on normal tissues.

The invention discloses a Zr-doped nickel-based electrocatalyst based on a 4, 4 '-dipyridyl chelating ligand and a preparation method and application thereof.The Zr-doped nickel-based electrocatalyst is characterized in that Ni < 2 + > serves as a central metal ion, 4, 4'-dipyridyl serves as the chelating ligand, and a stable coordination structure is constructed; zr is introduced as a doping element, and the electron density and the coordination environment of the catalyst are regulated and controlled by adjusting the doping proportion of Zr; and carbon fiber paper is used as a load electrode. A supported catalyst is prepared by using a constant-current electrodeposition method under a three-electrode system, and the catalyst is directly deposited on the surface of carbon fiber paper to form a self-supporting structure. The preparation method is simple in process, can be amplified on a large scale, and does not need a high-temperature roasting or complex solvent heat treatment step. The obtained catalyst is used for preparing adipic acid by electrocatalytic oxidation of cyclohexanol under an alkaline condition, and shows excellent catalytic activity and selectivity. The invention provides a green, efficient and low-cost adipic acid electrocatalytic synthesized novel electrocatalytic material, and the novel electrocatalytic material has a good industrial application prospect.

Compositions and methods for the removal and prevention of scale in pulp mills in a continuous and real-time process. More particularly the composition includes one or more chelating ligands, one or more copolymers, and one or more surfactants. The scale removing composition is added to the black liquor stream in pulp and paper processes to remove scaling, such as scaling from calcium carbonate, from surfaces in contact with the black liquor stream, such as in digestors and evaporators.

This invention relates to the field of chelating drug research, specifically to chelating ligand compounds, targeted chelating ligands and their complexes and applications. Compared with the prior art, the targeted molecule linking sites and linking methods disclosed in this invention have better targeting and in vivo stability. At the same time, the design of the targeted molecule linking sites in this invention can improve in vivo metabolism and distribution, thereby improving the druggability of preferred compounds and providing a better foundation for the clinical application of therapeutic radiopharmaceuticals.

The invention discloses a perovskite solar cell based on a multi-site chelate ligand and a preparation method thereof. The cell comprises an ITO conductive glass layer, a hole transport layer, a perovskite photoactive layer, a passivation layer, an electron transport layer and a metal electrode from bottom to top. The method is characterized in that a polydentate chelating ligand N, N '-ethylenediamine disuccinic acid (EDDS) is doped in a perovskite photoactive layer, and the ligand and uncoordinated Pb and Idefects on the surface of perovskite form stable coordinate bonds simultaneously through a plurality of carboxyl groups in molecules of the ligand, so that multi-site synergistic passivation is realized, and non-radiative recombination is effectively inhibited. The process is simple and is compatible with the existing spin coating process. The maximum power conversion efficiency of the obtained device can reach 24.57%, the initial efficiency of 90.2% can still be kept after continuous illumination for 3000 hours, and the device has high efficiency and high stability and is wide in application prospect.

The application belongs to the technical field of medical detection, and particularly relates to a polysaccharide contrast agent capable of renal metabolism and a preparation method thereof. The polysaccharide contrast agent has a structure as shown in formula (I), a particle size less than or equal to 8 nm, and can be rapidly metabolized through the kidney. The preparation method is to graft a metal macrocyclic ligand to a nano-crosslinked polysaccharide particle, and to prepare through a deprotection and metal ion chelation step. Since the contrast agent has the characteristic of renal metabolism, phagocytosis of the reticuloendothelial system is reduced, in vivo deposition of the contrast agent is reduced, and thus the biological safety is improved. Since a macrocyclic chelating ligand is used, good kinetic stability is achieved, the risk of in vivo metal ion deposition is reduced, and when applied to in vivo imaging, clear imaging of cardiovascular, lymph node, liver and other parts can be achieved. The preparation method is simple and easy to implement, reaction conditions are mild, is conducive to large-scale production and clinical transformation, and has a wide biomedical application prospect.

This invention provides a binder for a catalytic cracking catalyst and its preparation method. The binder comprises a binder, a curing agent, and a modifier. The curing agent is prepared by a hydrothermal reaction of a γ-alumina precursor, an acid, and an alkylammonium salt. The modifier is prepared by reacting a multi-metal chelate ligand, a metal central ligand, ethanol, and an organic acid. The binder comprises a phosphorus-containing compound and an aluminum-containing compound. In the binder for the catalytic cracking catalyst provided by this invention, a multi-metal chelate modifier composed of a multi-metal chelate ligand and multiple metals is introduced. Under the promotion of organic acid and ethanol, a multi-metal chelate modifier can be prepared in situ during the binder preparation process. Compared with directly using commercially available metal chelates, the in-situ prepared multi-metal chelate modifier has better water solubility and can promote the binding of the modifier with the phosphorus-aluminum sol, resulting in a better modification effect.

The invention provides an analysis method for measuring negative ions in urine based on gas phase ion chromatography, and belongs to the technical field of urine analysis. One of the urine analysis methods based on gas phase ion chromatography can comprise the following steps: injecting a chelating ligand into an analyzer through a continuous sample injector electrospray to obtain a background signal; a to-be-detected urine sample is fed one by one through an online six-way valve automatic sampler, a chelating ligand solution and the urine sample can be fully mixed through an online mixer, electrospray ionization is realized, the mixture enters an analyzer, an ion chromatograph records a sample signal, and a background is deducted to obtain a urine analysis result; wherein the ionization technology is an electrospray ion source. According to the method disclosed by the invention, separation of various ions on the gas phase ion chromatography can be realized; the kit can also be used for qualitatively and quantitatively detecting trace inflammatory factors, trace proteins and other proteins in urine, and can be applied to prevention and treatment of kidney stone.

The application relates to the technical field of electrocatalysis, in particular to a preparation method and application of a bismuth nanocrystal / nitrogen-rich graphite carbon electrocatalyst, which comprises the following steps: S1, adding urea and ammonium chloride into water, stirring, freeze-drying, grinding, and obtaining a chelating ligand; S2, adding bismuth citrate into the chelating ligand, carrying out a solid-phase reaction, and obtaining a precursor; and S3, calcining the precursor under nitrogen protection, and obtaining the bismuth nanocrystal / nitrogen-rich graphite carbon electrocatalyst. The problems that reduction and reconstruction reactions are prone to occur in the process of catalyzing CO2 electrocatalytic reduction, and the difficulty in increasing the recognition and performance regulation of active sites can be solved.

The invention discloses a preparation method and application of a semi-sandwich type iridium complex containing a tridentate ligand. The structural formula of the complex is shown as a formula (I), a ligand and a dimer react under the reaction condition, sodium bicarbonate is continuously added into a reaction system, proton H on coumarin unit carbon in the ligand can be selectively removed, and therefore the semi-sandwich type iridium complex (I) of the CNS tridentate ligand is obtained. Wherein a coordination carbon atom (C, blue) in the tridentate chelate ligand is derived from a coumarin unit, a nitrogen atom (N, red) is derived from a Schiff base structure, a sulfur atom (S, pink) is derived from thiosemicarbazide, the obtained iridium complex shows good anticancer activity, the performance of the iridium complex is close to or even superior to that of commercial cis-platinum, and the iridium complex is a very potential anticancer drug.

The present invention relates to a complex of formula (II) consisting of at least 90% of a diastereomeric excess comprising a mixture of II-RRR and II-SSS isomers of formulas: (see Formulas) (II-SSS) (II-RRR) The present invention also relates to a process for the preparation and purification of said complex of formula (II), as well as a composition comprising said complex.

A process may involve treating calcium sulfate separated from phosphoric acid with acid to obtain a suspension comprising purified calcium sulfate, separating the purified calcium sulfate in solid form from a liquid phase of the suspension, treating the purified calcium sulfate with water or with a salt- and / or chelate ligand-containing aqueous solution to leach rare earths out of the calcium sulfate, separating the further-purified calcium sulfate in solid form from the liquid phase of the suspension, mixing the purified calcium sulfate that is separated off with admixtures and reducing agents to obtain a raw meal mixture for cement clinker production, burning the raw meal mixture to obtain the cement clinker and thereby forming sulfur dioxide as offgas, and feeding the sulfur dioxide as raw material to sulfuric acid production to produce the sulfuric acid.

This invention relates to the application of compound A and its derivatives in the preparation of radiopharmaceuticals. The inventors discovered that compound A forms a chelated ligand compound with a target molecule via a linker, which then interacts with the radionuclide. 9 Zr、 47 Sc、 55 Co、 60 Cu、 61 Cu、 62 Cu、 64 Cu、 67 Cu、 66 Ga、 67 Ga、 68 Ga、 82 Rb、 86 Y、 87 Y、 90 Y、 97 Ru、 105 Rh、 109 Pd, 111 In、 117m Sn、 149 Pm, 52 Mn, 149 Tb, 152 Tb, 161 Tb, 99m Tc, 153 Sm、 177 Lu、 186 Re、 188 Re、 199 Au、 201 Tl、 203 Pb, 210 Pb, 212 Pb, 212 Bi、 213 Bi、 225 Ac、 223 Ra and 227 Th can form stable chelates labeled with radioactive metal nuclides under conditions without heating or low temperature. This chelation reaction is highly efficient, and the purity of the chelated product is greater than 95%. Furthermore, the resulting nuclide chelate derivatives exhibit low toxicity and good metabolic properties in vivo, indicating high clinical pharmaceutical potential.

The invention relates to a method for producing a MOF, wherein a MOF is a structured metal-organic compound comprising a bi- or tri-dimensional porous network consisting of inorganic entities that are connected by polydentate chelating ligands bonded to multiple metal centers; the polydentate chelating ligands being selected in particular from the group comprising C5-C24 heteroaromatic ligands and aromatic ligands, comprising at least one carboxylic acid function, preferably benzyl or naphthyl di-, tri- or tetracarboxylate, and the aromatic or heteroaromatic ligands optionally bearing, on at least one aromatic ring, a group selected from among —NH2, —OH, —CH3, —NO2, —CF3, —COOH, —SO3H, —SH, —OCH3.

The invention provides a CAIX ligand compound, a metal complex and application of the CAIX ligand compound and the metal complex, the structure of the compound is shown as a formula (A), and in the formula (A), R1 is selected from hydrogen or-L1-E1; r < 2 >, R < 3 >, R < 4 >, R < 5 >, R < 6 > and R < 7 > are independently selected from hydrogen or-L2-E2; each of the E1 and the E2 is independently a chelating ligand moiety; l1 and L2 are respectively and independently composed of a plurality of amino acid residues L; the basic fragment L0 of the amino acid residue L is selected from at least one of-Z-,-N (R8)-,-N (R8) 4,-C (= Z)-,-((C (R9) p) q-,-SO3H,-S (= O) j-,-NR8-C (= O)-,-NR8-C (= O)-NR8-,-C (= O)-NR8-,-((C (R9) p) q-Z) x-(C (R9) p) q-,-(C (R9) p) q-(Z-(C (R9) p) q) x-, alkylene, heteroalkylene, cycloalkylene, heterocyclic alkylene, arylene or heteroarylene; under a reasonable condition, a plurality of L0 are mutually spliced to form L, and one or more L can be mutually combined to form L1 or L2; or one or more L0 can be combined with each other to form L1 or L2. The compound provided by the invention can effectively optimize in-vivo pharmacokinetic characteristics and tumor retention capacity, and is used for developing and treating ccRCC.

This invention relates to cage-like chelates, targeted cage-like chelating ligands, their complexes, and applications. Breaking away from the cyclic structure of existing chelates, this invention boldly proposes and obtains a cage-like chelate. This chelate provides a more diverse range of modifiable sites and a more flexible framework structure, which we refer to as providing a "nuclear capsule," thus exhibiting broad-spectrum adaptability. Experiments have shown that the cage-like chelate and the targeted cage-like ligands it forms exhibit excellent stability after complexing with nuclides, effectively solving the toxic side effects caused by poor stability. When the radiopharmaceuticals formed by this invention are used as contrast agents for diagnosis or to utilize the α and β rays and Auger electrons generated by nuclides for therapeutic purposes, they exhibit higher targeting and stability, significantly improving the daughter nucleus recoil effect of alpha-nucleolabeled drugs in vivo and reducing the toxic side effects of alpha decay in normal tissues.

In some embodiments, the catalyst compound is represented by Formula (I): M is a Group 3-5 metal, a lanthanide metal atom, or an actinide metal atom. E is a substituted polycyclic aromatic hydrocarbon-based ligand bonded to M and is substituted with at least one ferrocenyl substituent bonded to the aromatic six-membered ring of the polycyclic aromatic hydrocarbon-based ligand. A is a monoanionic ligand bonded to M. And n is 0 or 1. T is bonded to A and E, and is a bridging group containing a Group 13, 14, 15, or 16 element, and is present when n is 1 and absent when n is 0. Each example of X is independently a monovalent anionic ligand, or two X are joined and bound to M to form a metal ring ring, or two X are joined to form a chelate ligand, a diene ligand, or an alkylene ligand.

This invention relates to the field of electroluminescence technology and discloses an organic electroluminescent device and its application. The organic electroluminescent device includes, from bottom to top, an anode layer, a first coordination-activated electron transport layer, an interface modification layer, a hole injection layer, a hole transport layer, an electron blocking layer, a light-emitting layer, a hole blocking layer, a second coordination-activated electron transport layer, an electron injection layer, and a cathode layer. The coordination-activated electron transport layer is composed of a non-alkali metal n-type dopant and an organic electron transport material, wherein the organic electron transport material is composed of a nitrogen-containing heterocyclic chelate ligand without lone pair electron-emitting unit modification. The coordination-activated electron transport layer of this invention possesses high conductivity and the function of controlling the optical microcavity of the device. During optical microcavity control, it does not significantly increase the device driving voltage, avoids pixel crosstalk caused by lateral current leakage, and works synergistically with the interface modification layer and the hole injection layer to solve the heterojunction interface energy level mismatch, thereby improving device lifetime and voltage stability.

The present invention relates to means and methods for conjugating / attaching target molecules such as proteins to a label and / or carrier. Specifically, the present invention provides a complex comprising a metal cation coordinating (i) nitrate as a metal cation ligand and (ii) a metal cation chelating domain comprising a chelating ligand and a label and / or carrier. This complex can be used for attaching a label and / or a carrier to a target molecule, preferably a protein. The attachment of the label or carrier via the complex of the invention involves the replacement of the metal cation ligand with a coordinating group of the target molecule so that a product complex with the target molecule as primary ligand in the coordination sphere of the metal cation is formed. Accordingly, the present invention also provides for uses and methods involving the attachment of a label and / or carrier to a target molecule. Also provided are the products obtained by the labeling and or carrier-attaching methods of the invention and uses thereof. The invention further relates to methods for producing the complex of the invention and kits comprising the components for producing the complex of the invention.

The invention discloses a titanium-aluminum sol preparation method, which comprises: mixing an aluminum source, a titanium tetrachloride waste liquid and deionized water, uniformly stirring to obtain a mixed solution, adding a dispersant and a modifier into the mixed solution, adjusting the pH value to 0-7, and aging to obtain a titanium-aluminum sol, the titanium-aluminum mass ratio of the titanium-aluminum sol being (0.5-6): 10, the modifier is one or more of a multi-tooth chelating ligand, a metal center ligand and organic acid. According to the method, the problem of treatment of the waste liquid containing titanium tetrachloride can be solved, and the obtained product can also be used as a binder with good performance.

Provided are a chelating ligand compound, a derivative and a preparation method therefor, a conjugate formed thereby and a use thereof. The chelating ligand compound has larger chelating space and a larger chelating capability, can form a stable structure with various metal ions, especially metal ions having a large atomic radius and much charge, thereby possessing higher in-vitro stability, and providing more possibilities for radiopharmaceutical therapy. Moreover, due to the large framework of the chelating ligand compound, high-temperature heating is not needed during metal nuclide labeling, thereby preventing the structure of the framework from being damaged in the heating process; additionally, the metal nuclide labeling process is simplified, thereby shortening the time, and increasing the radiochemical purity of a final target radiopharmaceutical.

This invention relates to the field of electrical insulation materials and special polymer coatings, specifically to a rare earth-modified wear-resistant enameled wire insulation coating and its preparation method; it comprises an insulating resin base, a rare earth-organic hybrid modifier, and an organic solvent; the coating uses a complex sol formed by the coordination of polysiloxane containing multidentate chelate ligands and reactive end groups with rare earth ions as the modifier; its core is to utilize the multidentate chelate ligands to covalently connect the polysiloxane skeleton and to firmly bind rare earth ions through coordination bonds, thereby constructing a stable and uniform molecular-level dispersed network structure; this invention abandons the traditional inorganic particle physical blending method, effectively suppressing the kinetic mismatch and gravity sedimentation defects caused by high-density rare earth phases, so that the liquid coating maintains excellent compatibility and uniformity during long-term storage.

The present invention relates to means and methods for conjugating / linking a target molecule such as a protein to a label and / or a carrier. Specifically, the present invention provides a complex comprising (i) a molecule selected from CO3 2‑ and HCO3 ‑ (ii) a carbonate metal cation ligand and (ii) a metal cation coordinated by a metal cation chelating domain, wherein the metal cation chelating domain comprises a chelating ligand and a label and / or a carrier. The complex can be used to connect the label and / or the carrier to a target molecule, preferably a protein. The connection of the label or the carrier through the complex of the present invention involves replacing the metal cation ligand with the coordination group of the target molecule, thereby forming a product complex with the target molecule as the main ligand in the coordination sphere of the metal cation. Therefore, the present invention also provides uses and methods including connecting the label and / or the carrier to the target molecule. Also provided are products obtained by the labeling and / or carrier connection method of the present invention and their uses. The present invention further relates to a method for producing the complex of the present invention and a kit comprising components for producing the complex of the present invention.

The present application relates to a chelated microparticle suitable for use in metal-chelate affinity chromatography. The chelated microparticle comprises a chelating ligand coupled to a support, the chelating ligand immobilizing a metal ion by means of coordination, the support having an effective hydroxyl group, and at least part thereof being a polymer microparticle of which internal pore channels have an at least partially ordered arrangement structure. Moreover, the present application further relates to a chromatographic medium containing the chelated microparticle. Compared with a traditional agarose matrix medium, in the chromatographic medium for the metal-chelate affinity chromatography technique of the present invention, polymer microparticles which have an at least partially ordered internal structure and pore channel distribution are used as supports, and the chromatographic medium has both a high dynamic binding capacity and a high mass transfer speed. In addition, an epoxy activation process is optimized, and the density of the coupled chelating ligands and immobilized metal ions is further increased. The chromatographic medium can tolerate conventional reagents, exhibits little metal ion leaching, and has a long service life, making the chromatographic medium suitable for further promotion and application.